Text
Size

Contrast

Back to Top Back to Top

Expand

Close

INDICATION

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

IMPORTANT SAFETY INFORMATION

You should not use BEOVU if you have an infection in or around the eye, eye inflammation, or if you are allergic to brolucizumab or any of the ingredients in BEOVU.

BEOVU is a prescription medicine given by injection into the eye. Injections in the eye, including BEOVU, may cause an infection of the eye or retinal detachment (separation of retina from the back of the eye). It is important to contact your doctor right away if your eye becomes red, sensitive to light, painful, or you develop a change in your vision.

Increased eye pressure has been seen within 30 minutes of an eye injection, including BEOVU. Sustained increases in eye pressure also have been reported. Your doctor should monitor for this when you receive a BEOVU injection.

There is a potential risk of stroke, heart attack, or blood clots in patients receiving eye injections of vascular endothelial growth factor (VEGF) inhibitor drugs, including BEOVU.

The most common side effects reported in patients receiving BEOVU were reduced clarity in vision, cataract, broken blood vessels in the eye, and vitreous floaters (moving spots in the field of vision).

You are encouraged to report negative side effects to FDA at www.fda.gov/medwatch or (800) FDA-1088.

Please see full Prescribing Information.

INDICATION

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).